#Cambridge #United Kingdom #STORM Therapeutics #STC-15 #Dr. Eric Martin

STORM Therapeutics Welcomes Dr. Eric Martin as Chief Development Officer

STORM Therapeutics Ltd., a pioneering clinical-stage company based in Cambridge, England, has made a significant leadership appointment with the introduction of Dr. Eric Martin as its Chief Development Officer (CDO). This strategic move aims to advance the company's groundbreaking efforts in cellular reprogramming through RNA modifications designed to treat various diseases, especially cancer.

Dr. Martin's impressive background spans over two decades of experience in oncology research and drug development, making him a well-qualified addition to the STORM leadership team. His extensive expertise includes specialization in biomarker-enabled preclinical discovery along with clinical development strategies, particularly focused on targeted and immuno-modulatory cancer therapies. This experience has resulted in the advancement of multiple oncology treatments into clinical trials, showcasing Dr. Martin's capability to bring innovative solutions to the cancer treatment landscape.

Before joining STORM, Dr. Martin held senior roles at prestigious biotech firms, such as Kinnate Biopharma, Plexxikon, and Pfizer Oncology. His formidable track record includes successfully guiding multidisciplinary teams through the complexities of drug discovery and early clinical development, demonstrating his adeptness in navigating the often challenging pathways of pharmaceutical innovation.

Jerry McMahon, the CEO of STORM Therapeutics, expressed enthusiasm regarding Dr. Martin's appointment, highlighting the importance of clinical genomics and biomarkers in the development of their pioneering METTL3 inhibitor, STC-15. This product is positioned to play a critical role in the fight against various cancers, and McMahon believes that Dr. Martin's insights and contributions will help expand treatment opportunities for this innovative therapy in specific patient populations.

In his new role, Dr. Martin will spearhead STORM's clinical development strategy. This includes progressing the METTL3 inhibitor, STC-15, which is currently undergoing Phase 1b/2 clinical trials. These trials explore the combination of STC-15 with LOQTORZI®, a next-generation PD-1 inhibitor, in treating patients with Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), melanoma, and endometrial cancers.

Dr. Martin's commentary on his new role indicates his excitement about STORM's achievements in RNA modifications, particularly the pioneering work on the METTL3 enzyme's implications in cancer progression. The clinical data published regarding STC-15 suggests its potential as a revolutionary treatment that could interrupt and suppress tumor development, representing a paradigm shift in addressing limitations of conventional therapies, including toxicity, durability, and resistance.

Dr. Martin's academic credentials reinforce his expertise; he holds a B.A. in Chemistry from the College of the Holy Cross and a Ph.D. in Genetics from Thomas Jefferson University’s Kimmel Cancer Institute. He additionally completed his postdoctoral training at Harvard Medical School's Dana-Farber Cancer Institute. Over the years, he has contributed significantly to the scientific community through numerous peer-reviewed publications, pivotal abstracts, and presentations.

About STORM Therapeutics

STORM Therapeutics is at the forefront of clinical-stage biotechnology focused on innovative cellular reprogramming techniques through RNA modifications to combat disease. The company prides itself on its leading understanding of RNA modifying enzymes (RME), which has catalyzed the development of breakthrough small molecule drugs aimed at reprogramming cells for treating cancer, inflammation, viral infections, and neurological diseases.
STORM's flagship product, STC-15, is the pioneering RNA modifying enzyme inhibitor under clinical evaluation. Currently in a Phase 1b/2 study combined with LOQTORZI®, it represents a beacon of hope for patients battling various malignancies. For further details about ongoing trials and the company’s innovative research, you can visit clinicaltrials.gov with the NCT identifier NCT06975293 and explore more on the company’s website at www.stormtherapeutics.com.